header logo image

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

September 13th, 2024 2:42 am

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company’s novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.

Continued here:
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

Related Post

Tags:

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick